Broad-spectrum vaccine based on H9 type avian influenza virus HA protein and preparation method

By designing modified HA proteins and using recombinant nucleic acid technology, the problem of the narrow protective spectrum of H9 avian influenza virus vaccines has been solved, and the induction of broad-spectrum cross-protective neutralizing antibodies has been achieved, making them easy to produce industrially.

CN122080148APending Publication Date: 2026-05-26POULTRY INSTITUTE SHANDONG ACADEMY OF AGRICULTURAL SCIENCE (SHANDONG SPECIFIC PATHOGEN FREE CHICKS RESEARCH CENTER) +1
2 Cites 0 Cited by

Patent Information

Application Number
CN202610077930.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-21
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing H9 avian influenza virus vaccines have a narrow spectrum of protection, making it difficult to cover historical circulating strains and proactively address future mutation trends. Furthermore, their complex production processes or limited safety profiles result in poor immune protection.

Method used

We designed and modified HA proteins, generated common amino acid sequences through multiple sequence alignment, and introduced neutralizing epitope insertion mutations and glycosylation site adjustments to construct a broad-spectrum vaccine. We then used recombinant nucleic acid molecules to efficiently express the vaccine in a eukaryotic system to prepare the broad-spectrum vaccine.

Benefits of technology

It achieves coverage of historical prevalent strains and prospective protection against future variants, induces high levels of broad-spectrum cross-protective neutralizing antibodies, and is easy to industrialize.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a modified hemagglutinin (HA) protein for preparing an H9 avian influenza broad-spectrum vaccine, a broad-spectrum vaccine based on the modified hemagglutinin (HA) protein, a preparation method, application and the like. The modified HA protein is obtained through the following strategy design: aiming at HA sequences of H9 avian influenza viruses in different epidemic periods, constructing consensus sequences as immunogen skeletons respectively; on the basis, two types of functional mutations are directionally introduced, one type is an epitope key residue targeted by transplanting a known broad-spectrum antibody, and the other type is a neutralizing epitope residue predicted based on a virus evolution law. The modified HA protein can maintain an overall folding and trimer interface highly similar to that of a wild type, can be efficiently expressed in an eukaryotic system, can be induced to generate a high-level neutralizing antibody with a broad-spectrum cross protection effect in a target animal body, provides a core antigen candidate for developing a new generation of H9 broad-spectrum vaccines, and has a wide application prospect. Wide application prospects are realized.
Need to check novelty before this filing date? Find Prior Art